Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia

NCT02300233 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02300233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02300233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 5, 2015
Completion date
January 24, 2017
Enrollment
114 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia